CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

COMPUGEN LTD

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026

$1.97+0.01 (+0.51%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 5.2
Dividend yield: –

COMPUGEN LTD cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Stock-Based Compensation	1.88	3.02	3.55	4.33	4.28	2.77	2.41	2.17	2.63	3.08	3.77	3.63	3.54	2.47	3.40	2.34	1.53
Change in Accounts Receivable	0.36	-0.21	-0.11	3.04	-2.80	-1.61	-0.14	-0.18	0.42	0.21	-7.80	–	–	–	–	–	–
Change in Accounts Payable	0.52	-1.67	1.73	-1.60	3.37	3.82	-3.50	2.69	1.56	-0.61	0.82	1.67	1.04	-0.09	-0.73	0.56	-1.53
Change in Unearned Revenue	36	44	37	–	–	–	–	–	–	-0.31	-1.48	-4.98	6.77	–	–	-0.11	0.01
Operating Cash Flow	32	50	-36	-34	-23	-28	-28	-13	-31	-20	-26	-11	-6.44	-11	-9.25	-4.28	-7.45
Capital Expenditures	-0.31	-0.12	-0.17	-0.48	-0.29	-0.17	-0.16	-0.16	-0.39	-2.60	-3.12	-1.90	-0.33	-1.01	-0.10	-0.05	-0.05
Sale of Property, Plant & Equipment	0.00	0.00	0	–	0.00	0.04	0.38	0.00	–	–	–	–	–	–	–	0.03	0.19
Purchase of Investments	-35	-64	-22	0	0	-152	-54	-62	-25	-51	-34	-82	-18	-3.22	-17	-15	-0.50
Sale & Maturity of Investments	50	53	10	0	0	70	59	27	72	69	47	18	3.22	17	15	0.50	2.61
Other Investing Activities	–	–	–	–	–	–	–	–	–	–	–	-0.10	–	-0.04	0.05	-0.05	0.02
Investing Cash Flow	30	-46	36	37	6.62	-82	5.33	-35	46	16	10	-64	-12	12	-1.23	-14	5.73
Stock Issued	11	0.54	3.08	0	15	74	23	28	–	–	–	71	20	6.21	–	7.79	12
Taxes Paid on Share-Based Awards	0.00	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	11	0.55	3.08	0.35	17	108	26	28	0.20	2.46	0.97	72	30	9.11	9.02	10	12
Foreign Exchange Rate Adjustments	0.14	0.07	0.13	-0.39	-0.06	–	–	–	–	–	–	–	–	–	–	–	–
Net Change in Cash	72	3.97	2.83	2.91	0.70	–	–	–	16	-1.15	-14	-3.11	12	11	-1.45	-7.84	10
Free Cash Flow	31	49	-36	-35	-23	-28	-28	-13	-31	-22	-29	-13	-6.77	-12	-9.35	-4.33	-7.50
Income Taxes Paid	0.06	14	0.01	–	–	–	–	–	–	0.02	0.39	0.36	0.50	–	–	–	–
Interest Paid	–	–	–	–	–	–	–	–	–	1.03	0.42	0.24	-0.11	-0.30	-0.35	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 87.3%
Operating margin: 43.1%
Net margin: 48.6%
Return on equity, FY2025: 44.8%

Financial strength

Current ratio: 5.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 45.4%

Valuation

P/E ratio: 5.2
Price to sales: –
Price to book: –
Dividend yield: –